Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
The five-year investment will go toward the construction of a new R&D facility in Beijing to develop innovative therapies and integrate the world’s second most populated country in the company’s ...
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
The Motley Fool on MSN4d
Is Pfizer Stock a Bargain for Long-Term Investors?Pfizer's 14% operational growth in non-COVID products shows the core business is stronger than many believe. The company's ...
Pfizer's diverse operations put it in an excellent position to grow in the long run. It doesn't have a top weight loss treatment on the market, but that could change. Its above-average dividend yield ...
Pharmaceutical giant Pfizer has agreed to pay $35 million to settle allegations that it unlawfully hindered the sale of Lipitor, a drug prescribed to lower ...
Pfizer Inc. failed to warn patients that its injectable contraceptive drug Depo-Provera can increase the risk of developing ...
With the total return of Pfizer's (NYSE: PFE) shares rising by just 1.9% this year so far, investors may be yearning for some ...
Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...
Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall Street estimates for third-quarter earnings on Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback